The novel prostate cancer antigen 3 (PCA3) biomarker

International Braz J Urol

Volumn 36, Issue 6, 2010, Pages 665-669

  Bourdoumis, Andreas ^a   Papatsoris, Athanasios G ^a   Chrisofos, Michael ^a   Efstathiou, Eleni ^b   Skolarikos, Andreas ^a   Deliveliotis, Charalambos ^a  

^a SISMANOGLIO HOSPITAL   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

Biopsy; PCA3; Prostatic neoplasms; PSA; Tumor marker

Indexed keywords

PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

BIOPSY; HUMAN; MALE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW; SENSITIVITY AND SPECIFICITY; URINE;

ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 79251503932     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000600003     Document Type: Review

References (21)

1. Reed AB, Parekh DJ: Biomarkers for prostate cancer detection. Expert Rev Anticancer Ther. 2010; 10: 103-14.
2. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al.: Predictive value of PCA3 in urinary sediments in determining clinicopathological characteristics of prostate cancer. Prostate. 2010; 70: 10-6.
3. Papatsoris A, Anagnostopoulos F: Prostate cancer screening behaviour. Public Health. 2009; 123: 69-71.
4. Schalken J: Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop. Eur Urol. 2006; 50: 153-4.
5. Hessels D, Schalken JA: The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol. 2009; 6: 255-61.
6. Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessels D, Schalken JA: Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate. 2010; 70: 70-8.
7. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al.: DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59: 5975-9.
8. Marks LS, Bostwick DG: Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Rev Urol. 2008; 10: 175-81.
9. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, et al.: A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008; 389: 1-6.
10. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al.: Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol. 2010; 183: 534-8.
11. Vlaeminck-Guillem V, Ruffon A, André J, Devonec M, Paparel P: Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010; 75: 447-53.
12. Kirby RS, Fitzpatrick JM, Irani J: Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int. 2009; 103: 441-5.
13. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al.: PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008; 179: 1587-92.
14. Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C: Precursor lesions of prostate cancer. Crit Rev Clin Lab Sci. 2007; 44: 243-70.
15. Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A: The Prostate Cancer gene 3 assay: indications for use in clinical practice. BJU Int. 2010; 105: 452-5.
16. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al.: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009; 56: 659-67.
17. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al.: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008; 180: 1975-8; discussion 1978-9.
18. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al.: Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008; 180: 1303-8. discussion 1308.
19. Erratum in: J Urol. 2009; 181: 1507.
20. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al.: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54: 1081-8.
21. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ: PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology. 2009; 73: 363-8.